Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34588

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34588

Title:	Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
Authors:	Chang, Wei-Ting Hong, Chon-Seng Hsieh, Kun-Lin Chen, Yi-Chen Ho, Chung-Han Shih, Jhih-Yuan Kan, Wei-Chih Chen, Zhih-Cherng Lin, You-Cheng
Contributors:	Chi Mei Hospital Southern Taiwan University of Science & Technology National Cheng Kung University Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chi Mei Hospital National Cheng Kung University Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Chi Mei Hospital Chung Hua University Chi Mei Hospital
Keywords:	agonists mortality disease men testosterone taiwan impact
Date:	2022
Issue Date:	2023-12-11 13:59:20 (UTC+8)
Publisher:	FRONTIERS MEDIA SA
Abstract:	Gonadotropin-releasing hormone (GnRH) therapy has been known to increase risks of major adverse cardiovascular and cerebrovascular events (MACCEs). Herein, we aim to estimate whether regular use of aspirin attenuates risks of MACCEs in prostate cancer patients receiving GnRHs. Using Taiwanese National Health Insurance Research Database (NHIRD), we identified 7719 patients diagnosed with prostate cancer who were either aspirin-naive, received irregular or regular aspirin from 2008 to 2015. Through a multivariable logistic regression model, we investigated the impact of aspirin on MACCEs. Compared with nonusers and irregular users, most patients receiving regular aspirin were older and had more comorbidities. The crude incidence of one-year MACCEs was lowest in aspirin nonusers but highest in irregular users of aspirin compared with regular users of aspirin (2.65% vs. 4.41% vs. 2.85%, p=0.0099). After adjusting for age, cancer stage and comorbidities, irregular aspirin users had a higher risk of one-year MACCEs (adjusted OR: 1.33; 95% CI: 0.93-1.90, p=0.1139) than aspirin nonusers, but conversely, there was a trend of reducing the risk of MACCEs among those who received regular aspirin (adjusted OR: 0.79; 95% CI: 0.44-1.42, p=0.4256). In the subgroup analysis, there were age- and cancer stage-independent higher risks of MACCEs in patients who took aspirin irregularly compared to those in patients who did not take aspirin. The risks were attenuated in patients receiving regular aspirin. Collectively, regular use of aspirin presented a trend of reducing risks of MACCEs in prostate cancer patients receiving GnRHs. However, irregular use of aspirin diminished the benefits.
Relation:	FRONTIERS IN ONCOLOGY, v.12, n.CB2, pp.CC2, pp.-2874,
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
fonc.2022.952370.pdf		668Kb	Adobe PDF	57	View/Open
index.html		0Kb	HTML	349	View/Open

Loading...